Colistin: The revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections

Clinical Infectious Diseases

Volumn 40, Issue 9, 2005, Pages 1333-1341

  Falagas, Matthew E ^a,b,c   Kasiakou, Sofia K ^a  

^a HENRY DUNANT HOSPITAL   (Greece)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AZLOCILLIN; AZTREONAM; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; COLY MYCIN M; COTRIMOXAZOLE; IMIPENEM; PHENYLALANINE; PIPERACILLIN; POLYMYXIN B; POLYMYXIN DERIVATIVE; PROMIXIN; RIFAMPICIN;

ACINETOBACTER; ACUTE KIDNEY TUBULE NECROSIS; ALLERGIC REACTION; APNEA; ATAXIA; BACTEREMIA; BACTERIAL STRAIN; CLINICAL PRACTICE; CLINICAL TRIAL; CONFUSION; CREATININE BLOOD LEVEL; CYSTIC FIBROSIS; DIZZINESS; DRUG SAFETY; DRUG STRUCTURE; ENTEROBACTER; FEVER; GASTROINTESTINAL DISEASE; GRAM NEGATIVE INFECTION; HUMAN; HYPERSENSITIVITY REACTION; KLEBSIELLA; MULTIDRUG RESISTANCE; MUSCLE WEAKNESS; NEPHROTOXICITY; NEUROMUSCULAR BLOCKING; NEUROTOXICITY; PARESTHESIA; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; PSEUDOMONAS AERUGINOSA; RASH; RESPIRATORY FAILURE; REVIEW; SIDE EFFECT; URINARY TRACT INFECTION; URTICARIA; VERTIGO; VISUAL DISORDER;

ANTI-BACTERIAL AGENTS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS;

EID: 17644389620     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/429323     Document Type: Review

References (81)

1. Storm DR, Rosenthal KS, Swanson PE. Polymyxin and related peptide antibiotics. Annu Rev Biochem 1977; 46:723-63.
2. Nakajima S. Clinical use of colimycin F otic solution [in Japanese]. Jibiinkoka 1965; 37:693-7.
3. Ohzawa R. The use of colimycin ear drops [in Japanese]. Jibiinkoka 1965; 37:585-90.
4. Komura S, Kurahashi K. Partial purification and properties of L-2,4-diaminobutyric acid activating enzyme from a polymyxin E producing organism. J Biochem (Tokyo) 1979; 86:1013-21.
5. Koyama Y, Kurosasa A, Tsuchiya A, Takakuta K. A new antibiotic "colistin" produced by spore-forming soil bacteria. J Antibiot (Tokyo) 1950; 3:457-8.
6. Reed MD, Stern RC, O'Riordan MA, Blumer JL. The pharmacokinetics of colistin in patients with cystic fibrosis. J Clin Pharmacol 2001; 41:645-54.
7. Brown JM, Dorman DC, Roy LP. Acute renal failure due to overdosage of colistin. Med J Aust 1970; 2:923-4.
8. Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium colistimethate: manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 1970; 72:857-68.
9. Ryan KJ, Schainuck LI, Hickman RO, Striker GE. Colistimethate toxicity: report of a fatal case in a previously healthy child. JAMA 1969; 207:2099-101.
10. Conway SP, Pond MN, Watson A, Etherington C, Robey HL, Goldman MH. Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis. Thorax 1997; 52:987-93.
11. Cunningham S, Prasad A, Collyer L, Carr S, Lynn IB, Wallis C. Bronchoconstriction following nebulised colistin in cystic fibrosis. Arch Dis Child 2001; 84:432-3.
12. Ledson MJ, Gallagher MJ, Cowperthwaite C, Convery RP, Walshaw MJ. Four years' experience of intravenous colomycin in an adult cystic fibrosis unit. Eur Respir J 1998; 12:592-4.
13. Katz E, Demain AL. The peptide antibiotics of Bacillus: chemistry, biogenesis, and possible functions. Bacteriol Rev 1977; 41:449-74.
14. Decolin D, Leroy P, Nicolas A, Archimbault P. Hyphenated liquid chromatographic method for the determination of colistin residues in bovine tissues. J Chromatogr Sci 1997; 35:557-64.
15. Orwa JA, Govaerts C, Busson R, Roets E, Van Schepdael A, Hoogmartens J. Isolation and structural characterization of colistin components. J Antibiot (Tokyo) 2001; 54:595-9.
16. Barnett M, Bushby SR, Wilkinson S. Sodium sulphomethyl derivatives of polymyxins. Br J Pharmacol 1964; 23:552-74.
17. Beveridge EG, Martin AJ. Sodium sulphomethyl derivatives of polymyxins. Br J Pharmacol 1967; 29:125-35.
18. Davis SD, Iannetta A, Wedgwood RJ. Activity of colistin against Pseudomonas aeruginosa: inhibition by calcium. J Infect Dis 1971; 124:610-2.
19. Newton BA. The properties and mode of action of the polymyxins. Bacteriol Rev 1956; 20:14-27.
20. Schindler M, Osborn MJ. Interaction of divalent cations and polymyxin B with lipopolysaccharide. Biochemistry 1979; 18:4425-30.
21. Koike M, Iida K, Matsuo T. Electron microscopic studies on mode of action of polymyxin. J Bacteriol 1969; 97:448-52.
22. Gough M, Hancock RE, Kelly NM. Antiendotoxin activity of cationic peptide antimicrobial agents. Infect Immun 1996; 64:4922-7.
23. Moore RA, Chan L, Hancock RE. Evidence for two distinct mechanisms of resistance to polymyxin B in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1984; 26:539-45.
24. 2+ environments. J Bacteriol 1997; 179:7040-5.
25. Moore RA, Hancock RE. Involvement of outer membrane of Pseudomonas cepacia in aminoglycoside and polymyxin resistance. Antimicrob Agents Chemother 1986; 30:923-6.
26. Denton M, Kerr K, Mooney L, et al. Transmission of colistin-resistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis center. Pediatr Pulmonol 2002; 34:257-61.
27. Gunn JS, Lim KB, Krueger J, et al. PmrA-PmrB-regulated genes necessary for 4-aminoarabinose lipid A modification and polymyxin resistance. Mol Microbiol 1998; 27:1171-82.
28. Bengoechea JA, Skurnik M. Temperature-regulated efflux pump/potassium antiporter system mediates resistance to cationic antimicrobial peptides in Yersinia. Mol Microbiol 2000; 37:67-80.
29. Ito-Kagawa M, Koyama Y. Selective cleavage of a peptide antibiotic, colistin by colistinase. J Antibiot (Tokyo) 1980; 33:1551-5.
30. Renard L, Sanders P, Laurentie M. Pharmacokinetics of colistin sulfate administered by intravenous and intramuscular routes in the calf [in French]. Ann Rech Vet 1991; 22:387-94.
31. Yamada S, Mayahara T, Mitsuhashi N, Wakabayashi K, Hiratsuka K. Fundamental studies on colistin sodium methanesulfonate (colimycin). I. On the blood level, distribution, and excretion of CL-M [in Japanese]. Jpn J Antibiot 1974; 27:8-14.
32. al Khayyat AA, Aronson AL. Pharmacologic and toxicologic studies with the polymyxins. II. Comparative pharmacologic studies of the sulfate and methanesulfonate salts of polymyxin B and colistin in dogs. Chemotherapy 1973; 19:82-97.
33. Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration. Antimicrob Agents Chemother 2003; 47:1766-70.
34. Li J, Turnidge J, Milne R, Nation RL, Coulthard K. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 2001; 45:781-5.
35. Li J, Coulthard K, Milne R, et al. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J Antimicrob Chemother 2003; 52:987-92.
36. Catchpole CR, Andrews JM, Brenwald N, Wise R. A reassessment of the in-vitro activity of colistin sulphomethate sodium. J Antimicrob Chemother 1997; 39:255-60.
37. McMillan FH, Pattison IC. Sodium colistimethate. I. Dissociations of aminomethanesulfonates in aqueous solution. J Pharm Sci 1969; 58:730-7.
38. Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K. Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography. Antimicrob Agents Chemother 2003; 47:1364-70.
39. Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother 2004; 53:837-40.
40. Kunin CM, Bugg A. Binding of polymyxin antibiotics to tissues: the major determinant of distribution and persistence in the body. J Infect Dis 1971; 124:394-400.
41. Craig WA, Kunin CM. Significance of serum protein and tissue binding of antimicrobial agents. Annu Rev Med 1976; 27:287-300.
42. al Khayyat AA, Aronson AL. Pharmacologic and toxicologic studies with the polymyxins. 3. Consideration regarding clinical use in dogs. Chemotherapy 1973; 19:98-108.
43. Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration. Antimicrob Agents Chemother 2003; 47:1766-70.
44. Ziv G, Nouws JF, van Ginneken CA. The pharmacokinetics and tissue levels of polymyxin B, colistin and gentamicin in calves. J Vet Pharmacol Ther 1982; 5:45-58.
45. Jimenez-Mejias ME, Pichardo-Guerrero C, Marquez-Rivas FJ, Martin-Lozano D, Prados T, Pachon J. Cerebrospinal fluid penetration and pharmacokinetic/ pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis. Eur J Clin Microbiol Infect Dis 2002; 21:212-4.
46. Gales AC, Reis AO, Jones RN. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol 2001; 39:183-90.
47. Niks M, Hanzen J, Ohlasova D, et al. Multiresistant nosocomial bacterial strains and their "in vitro" susceptibility to chloramphenicol and colistin [in Czech]. Klin Mikrobiol Infekc Lek 2004; 10:124-9.
48. Hogardt M, Schmoldt S, Gotzfried M, Adler K, Heesemann J. Pitfalls of polymyxin antimicrobial susceptibility testing of Pseudomonas aeruginosa isolated from cystic fibrosis patients. J Antimicrob Chemother 2004; 54:1057-61.
49. Rastogi N, Potar MC, David HL. Antimycobacterial spectrum of colistin (polymixin E). Ann Inst Pasteur Microbiol 1986; 137A:45-53.
50. Rastogi N, Henrotte JG, David HL. Colistin (polymyxin E)-induced cell leakage in Mycobacteriurn aurum. Zentralbl Bakteriol Mikrobiol Hyg [A] 1987; 263:548-51.
51. ++ efflux in Mycobacterium avium and its effects on drug-susceptibility. Zentralbl Bakteriol Mikrobiol Hyg [A] 1988; 268:251-8.
52. Colomycin [package insert]. Bexley, UK: Forest Laboratories, UK Limited, 2002.
53. Kasiakou SK, Rafailidis PI, Liaropoulos K, Falagas ME. Cure of posttraumatic recurrent multiresistant gram-negative rod meningitis with intraventricular colistin. J Infect (in press).
54. Michalopoulos A, Kasiakou SK, Mastora Z, Rellos K, Kapaskelis AM, Falagas ME. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant gram-negative bacteria in patients without cystic fibrosis. Crit Care 2005; 9:R53-9.
55. Littlewood JM, Koch C, Lambert PA, et al. A ten year review of colomycin. Respir Med 2000; 94:632-40.
56. Hamer DH. Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin. Am J Respir Crit Care Med 2000; 162:328-30.
57. Coly-mycin M patenteral [package insert]. Bristol, TN: Monarch Pharmaceuticals, 2002.
58. Michalopoulos A, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME. Colistin treatment in patients with ICU-acquired infections caused by multiresistant gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 2005; 11:115-21.
59. Markou N, Apostolakos H, Koumoudiou C, et al. Intravenous colistin in the treatment of sepsis from multiresistant gram-negative bacilli in critically ill patients. Crit Care 2003; 7:R78-83.
60. Michalopoulos A, Kasiakou SK, Rosmarakis ES, Falagas ME. Cure of multidrug-resistant Acinetobacter baumannii bacteremia with continuous intravenous infusion of colistin. Scand J Infect Dis 2005 37:142-5.
61. Promixin 1 MIU powder for nebuliser solution [package insert]. West Sussex, UK: Profile Pharma Limited, 2003.
62. Weber A, Morlin G, Cohen M, Williams-Warren J, Ramsey B, Smith A. Effect of nebulizer type and antibiotic concentration on device performance. Pediatr Pulmonol 1997; 23:249-60.
63. Faurisson F, Dessanges JF, Grimfeld A, et al. Nebulizer performance: AFLM study. Association Francaise de Lutte contre la Mucoviscidose. Respiration 1995; 62(Suppl 1):13-8.
64. Benifla M, Zucker G, Cohen A, Alkan M. Successful treatment of Acinetobacter meningitis with intrathecal polymyxin E. J Antimicrob Chemother 2004; 54:290-2.
65. Fernandez-Viladrich P, Corbella X, Corral L, Tubau F, Mateu A. Successful treatment of ventriculitis due to carbapenem-resistant Acinetobacter baumannii with intraventricular colistin sulfomethate sodium. Clin Infect Dis 1999; 28:916-7.
66. Vasen W, Desmery P, Ilutovich S, Di Martino A. Intrathecal use of colistin. J Clin Microbiol 2000; 38:3523.
67. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003; 36:1111-8.
68. Levin AS, Barone AA, Penco J, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999; 28:1008-11.
69. Bosso JA, Liptak CA, Seilheimer DK, Harrison GM. Toxicity of colistin in cystic fibrosis patients. DICP 1991; 25:1168-70.
70. Price DJ, Graham DI. Effects of large doses of colistin sulphomethate sodium on renal function. Br Med J 1970; 4:525-7.
71. Randall RE, Bridi GS, Setter JG, Brackett NC. Recovery from colistimethate nephrotoxicity. Ann Intern Med 1970; 73:491-2.
72. Falagas ME, Rizos M, Bliziotis IA, Rellos K, Kasiakou SK, Michalopoulos A. Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect Dis 2005; 5:1.
73. Kasiakou SK, Michalopoulos A, Soteriades E, Samonis G, Sermaides G, Falagas ME. Intravenous colistin for treatment of infections due to multidrug-resistant gram-negative bacteria in patients without cystic fibrosis [P 1074]. In: Proceedings of the 15th European Congress of Clinical Microbiology and Infectious Diseases (Copenhagen). 2005.
74. Al Aloul M, Miller H, Alapati S, Stockton PA, Ledson MJ, Walshaw MJ. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use. Pediatr Pulmonol 2005; 39:15-20.
75. Gunderson BW, Ibrahim KH, Hovde LB, Fromm TL, Reed MD, Rotschafer JC. Synergistic activity of colistin and ceftazidime against multiantibiotic- resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2003; 47:905-9.
76. Tascini C, Ferranti S, Messina F, Menichetti F. In vitro and in vivo synergistic activity of colistin, rifampin, and amikacin against a multiresistant Pseudomonas aeruginosa isolate. Clin Microbiol Infect 2000; 6:690-1.
77. Tascini C, Gemignani G, Ferranti S, et al. Microbiological activity and clinical efficacy of a colistin and rifampin combination in multidrug-resistant Pseudomonas aeruginosa infections. J Chemother 2004; 16:282-7.
78. Giamarellos-Bourboulis EJ, Karnesis L, Giamarellou H. Synergy of colistin with rifampin and trimethoprim/sulfamethoxazole on multidrug-resistant Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis 2002; 44:259-63.
79. Wright WW, Welch H. Chemical, biological and clinical observations on colistin. Antibiot Annu 1959; 7:61-74.
80. Hoeprich PD. The polymyxins. Med Clin North Am 1970; 54:1257-65.
81. Nord NM, Hoeprich PD. Polymyxin B and colistin: a critical comparison. N Engl J Med 1964; 270:1030-5.